Virus a potential future cancer medicine

September 16, 2011

In a new project, researchers from LIFE - the Faculty of Life Sciences at the University of Copenhagen - document that the vesicular stomatitis virus (VSV) plays a previously unknown dual role in the prevention of a number of cancers. The new findings show that the virus both kills cancer cells and stops the expression of the molecules which certain types of cancer cells produce to hide from the immune system.

Certain types of cancer cells express far too many liquid immunostimulatory molecules, blocking the immune system's ability to recognise them, and enabling them to continue the development of cancer

"The overexpression seen in cancer types such as melanoma, testicular cancer, ovarian cancer and certain types of leukaemia significantly impairs the immune system, thereby reducing the patient's chance of recovery," says Associate Professor in immunology Søren Skov from LIFE.

Søren Skov is heading a research team which has just launched a major EU project to study the potential for improving cancer treatment by strengthening the immune system.

As part of the research project, PhD student Helle Jensen has infected human cancer cells with VSV.

"We were able to demonstrate that the virus kills cancer cells. The results also show that VSV effectively blocks the production of the immunostimulatory molecules which certain types of cancer overexpress to destroy the immune system and thus the chances of survival," Associate Professor Skov says.

This is a clear breakthrough and a giant leap towards better cancer treatment. The immune system will be able to more effectively stop the development of cancer when not sidelined. In addition, it is possible to mutate the virus and thus adapt it to the relevant type of cancer. There is thus a potential for a future alternative to chemotherapy, tailored to the individual patient, says Associate Professor Søren Skov.

"The next step will be clinical trials in humans. Such trials are already being conducted in the USA," says Helle Jensen, who has carried out the research project at LIFE in collaboration with the Faculty of Health Sciences at the University of Copenhagen and the National Veterinary Institute at the Technical University of Denmark (DTU).
-end-
Contact:

Associate Professor Søren Skov
Mobile: +45 28 75 76 79
Email: sosk@life.ku.dk

PhD student Helle Jensen
Mobile: +45 23 80 57 54
Email: hejen@life.ku.dk

University of Copenhagen

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.